2013 - 2017
Subclone Expansion and Evolution in Ph+ CML and other MPN
The project part leader, Thomas Lion, has a long-lasting interest in Ph+ CML and is well known and well-embedded in the scientific community. Early in his career, he developed robust technologies for the MRD detection in CML. Since then, his lab and team have been a well-known top reference center for BCR/ABL quantification, and are well-known for their innovative research efforts. Thomas established methodologies for the reliable quantification of BCR/ABL mutant-bearing CML subclones by employing a ligase-dependent PCR assay.
Using patient samples, this technique turned out to represent a “next-generation” technology for the measurement of evolution, expansion, and depletion of LSC-derived (naturally persistent) subclones in Ph+ CML during treatment with BCR/ABL TKI. Thomas Lion is head of the Division of Molecular Diagnostics at the Children’s Cancer Research Institute (CCRI) Vienna, and Medical Director of LabDia Diagnostics (Vienna, Austria). In the SFB, the group examined and defined what molecular lesions and aberration profiles contribute to or even induce subclone evolution and subclone expansion in Ph+ CML and Ph- MPN.